Statement of Deviation for the half year ended March 31, 2025 pursuant to Regulation 32 of the SEBI (LODR) Regulation, 2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Valencia Nutrition has filed a Nil Statement of Deviation, confirming that there has been no deviation or variation in the use of money raised through its past fundraisings. The first annexure relates to the Rights Issue of April 23, 2024, which raised Rs. 21.78 crore, of which Rs. 20.43 crore was deployed across unsecured loan adjustment (Rs. 3.00 crore), working capital (Rs. 12.35 crore) and general corporate purposes (Rs. 5.08 crore). The second annexure covers the Preferential Issue and Convertible Warrants of January 28, 2025 — Rs. 12.07 crore from equity shares plus Rs. 20.00 crore from warrants (of which only the minimum 25%, i.e. Rs. 5.00 crore, has been received so far). Of this, Rs. 9.22 crore has been utilised, mainly towards setting up a manufacturing unit (Rs. 7.26 crore) and new product development (Rs. 0.83 crore). The statement has been reviewed by the Audit Committee and signed by Whole-Time Director & CFO Jay Shah.
This is a routine compliance filing with no negative news. It reassures shareholders that capital raised via the Rights Issue and the Preferential Issue/Warrants is being used exactly as disclosed, which is mildly positive for governance and transparency. No material impact on the stock price is expected from this disclosure.